Welcome and good morning on our behalf as well. We will directly go into some of the overall highlights as usual. And we have, uh, we gave this quarterly report the headline 'Stable Demand in a Challenging Quarter'. And by challenging we referred to, uh, that Q1 in 2023 was a very strong quarter and is now a difficult reference. We have some Easter effect and uh, also some headwind in certain segments and all of this I will obviously elaborate more on. But back to the highlights and the comments. So there was a stable order intake growth of plus 0% in total, whereof -3% organically. And to comment on some of the. Sectors and segments. We saw good demand in the med tech area. Pharmaceutical area. And also in terms of energy and the process industry. In terms of sales, we were down 4% and organically -6%. And again, this was mainly due to strong references and fewer working days. This led to an EBITA margin of 13.3%. Not a level where we want to be. But again, I will talk a bit more about this later on here. The inventory level was quite stable from Q4 2023, so sequentially flat. And a very good acquisition pace. Five acquisitions completed in quarter one and seven so far in the year here. And I would say that the inflow of interesting companies to acquire is strong. But I'm sure many of you are keen to understand more about the market perspective. And, uh. On this slide here, you see both order intake and sales next to each other. And, uh. The bars refer to the absolute numbers, and the yellow line is, uh, the growth line organically. Uh, and you can see now, in terms of the bars there that we have had a growing order intake, uh, and a fairly good order intake in Q4, uh, last year and Q1 now this year in relation to, to sales, which, uh, which has been a little bit weaker there, and hence we have built some, some order book. Uh. But, uh, I would say continued, uh, aggregated stable, high demand and, uh, order intake, as I said, in line with previous year and Q4 2023. And just to give some context to 2023 order intake. At that point in quarter one was in total up 14% and organically plus 3%. And as usual for Indutrade, we have seen variation between companies, segments, and countries. And we have had a positive book to build now two quarters in a row, where orders now were 4% higher than sales. So, you have to take the numbers. Plus 0% in total, -3% organically, plus 3% from acquisitions. Minus 1% from divestments and plus 1% related to currency. And, talking a bit about sectors and segments. As I said, companies with customers in pharmaceutical production had their strongest order intake. Demand was also good within the process industry and the energy segment. As many of you know, we have a cluster of companies linked to the Novo Nordisk capacity increases. And that's still obviously ongoing to a very large extent. But the projects are large and complex, and there are some delays being experienced there. So, I would say that we weren't able really to invoice and ship to the extent which we had planned some months ago. In general, I've said this many times before. In general, the green transformation is still driving a lot of investments and also business activity in general, which is positive for a large part of our companies, not least the process, energy, and water business area. The organic order intake in infrastructure and construction was still weak and has been weak now for some quarters, predominantly in the construction area. This quarter, we have also experienced a bit weaker demand from the engineering segment. If we then turn to sales. Again, strong references. And it was even stronger on the sales side than the order intake side. Q1 2024 sales increased 26% in total and plus 13% organically. So, it's really difficult comparisons here. And we came in this quarter -4% in total and -6% organically, plus 3% from acquisitions, -1% from divestments and the impact from currency was basically flat. And this time, only one of our five business areas was able to grow organically. And that was process, energy, and water. And again, based on, to a large extent, I would say, the green transformation and predominantly the Nordic region, Life Science had very strong references, a lot of all-time highs in our companies in terms of sales last year. And again, as I said, there's a bit of delays linked to the Novo Nordisk, potential invoicing, shipping, and also lower activity in terms of single-use in the pharma production, we had a great business linked to that a year ago. And now it's dramatically lower. And part of that can be explained by less. With orientation. And again, a continued challenging market situation for the infrastructure and construction area. If we look at sales more in a market perspective, what market countries we sell into. You see that we have divided this into a Nordic cluster, something we call rest of Europe, and then rest of the world. And there, we are, since several quarters back, stronger or we are experiencing a stronger market situation in the Nordics versus the more central European countries. Uh, and within the Nordics, it's actually this quarter been Norway, which has been the best market. And in Norway, I would say that the energy segment stands out positively and otherwise. It's a rather okay situation overall. Otherwise, Sweden, Denmark, Finland were more flattish. Obviously, differences between sectors in these countries. In Sweden, we have had a good life science situation, but the construction sector was weak; the rest has been more flattish in Denmark. It's been quite okay in terms of process, energy, and water. Some of our companies there have built new business in Iceland where we really haven't been strongly present before, which has been positive. And, as I said, Denmark would probably have been a little bit stronger with an arrow up if there had been more invoicing linked to this Novo Nordisk cluster in Finland, we also see a weaker construction area, also slightly weaker engineering segment. And obviously there's been a strike, as you all know, in Finland this quarter. And that has also had some impact there. And if we turn to the rest of Europe, it is somewhat weaker. In the Benelux area and Germany, we see weaker single-use invoicing. And that's sort of driving the arrows down otherwise fairly flattish situations in the UK. Energy and defence are positive, construction weaker. In Switzerland and to some extent, Austria. We have also seen a weaker situation in the construction segment. Also life science and process, energy, and water. And we are not really present in the other sectors in Switzerland, Austria. You're fairly relatively small in North America and Asia, so large individual orders can have some impact. But, in general, the business climate is stronger in North America. That's why the arrow is up there. And, in Asia, prominently China, a bit of a weaker business situation. If we then turn to our financial performance in terms of EBIT, obviously the organic sales development is the main driver for the EBIT decline. Again, the strong references and the Easter effects had an impact there; in absolute terms, our EBITA came in at 1.1 billion SEK, a decrease of 16% and 19% organically, and plus 3% from acquisitions, 0% from divestments, and 0% linked to currency. It was actually comforting to see that our gross margin was improving this quarter. It's actually been our best gross margin level since Q4 2021. So good work in terms of that. However, we also experienced higher expense levels. And here we are not equally proud. And, uh, I could say that cost management will be important, uh, going forward. I think we, uh, were a little bit too much on our heels versus on our toes in this quarter. Linked to the cost side. All of you basically know that from the beginning of the year, we introduced a new, uh, group structure. Uh, we went from eight business areas to five international business areas. And, uh, the intention with this is, uh, basically to fuel, uh, growth medium term, long term, not any expected short term impact. And, uh, the organization is obviously launched and implemented, and the structure is based on being more outside-in market-driven in terms of these new sectors. And all the sectors are then divided into approximately 30 segments. Uh, we have definitely still kept the individual company at the core of Indutrade. So we are more building a, you can say, a support and development structure around the companies. Uh, and the companies are now grouped into more relevant segments where they can learn from each other and gain knowledge from each other in a better way. We also think that this can and should drive positive acquisition activity. We can more clearly see now where we potentially have what we call white spot areas in these 30 segments and then build acquisition plans in a structured way linked to that. Uh, I also think this structure provides more clarity about the trading and external perspective. It's intuitively more, uh, easy, I would say to understand what, uh, what we are all about and in what sectors we are present. So if we then turn to the performance in the five different business areas, uh. I would say that all of them are obviously impacted by fewer working days and strong references, but in particular the life science area. They had an extremely strong, uh, quarter one last year and not least then linked to this single-use area. Infrastructure and construction continues to have a challenging market situation. And in this business area, total sales were also affected negatively by the divestment of the Dutch company Cubic, which we made late last year, and that had an impact of -8%. Uh, and this is not new, that there has been headwind in the construction sector for some quarters now. And, uh, I would also say that the winter this. Quarter or the quarter. First quarter of this year in the Nordics has been quite challenging in terms of construction work. The weaker general engineering and also construction work had an impact on industrial and engineering and also technology and system solutions more broadly. And uh, and uh, I would say more evidently this quarter than in 2023, uh, but, uh, process, energy, and water managed to grow organically and, and driven mainly by the process industry and the energy segments in the Nordic area. And if we look at the EBITA in a business area perspective, uh, all areas were impacted by the weak organic sales development and uh, EBITA margin declined for all business areas, but only very marginally for process, energy, and water. Life science, as discussed before, had the most challenging references and the lower organic sales for companies selling to the pharmaceutical production. Single-use had a really stronger impact on the margin here. Good pricing work and, uh, impacting the gross margin positively. And again, it came in at 35% versus 34.6% a year ago. So, strong level here. But the margin, the EBITA margin, was reduced or dampened by our increased expense level. And, we have obviously experienced cost inflation in general. And, this needs to be managed. And, I am not completely satisfied with our performance here this quarter. If we then leave the financials and the business areas and turn to acquisitions, more of a happy face, happy situation, I would say a really good start in 2024. And, we have now been able to acquire seven well-managed, successful companies. And if we add their total sales annually, it adds up to 775 million SEK. And, four out of five business areas have been engaged in acquisitions. And we have a number of projects right now in different phases ongoing, which is positive for the coming quarters. And as we have said before, we have generally strengthened our acquisition resources since some quarters now. And we have built also some professional resources in Northern Italy, and hope to see positive effects of that going forward. Also, the general pipeline remains strong, and the inflow of new companies is positive. So all in all, I'm quite optimistic that 2024 will be a good acquisition year. On this slide here, you can see our performance in terms of the number of companies acquired and also the quarterly financial effects from acquisitions. How much, basically how much EBITA we have added in a single quarter here. And, in the slide, towards the right, you see that we have added around 30 million SEK in quarter one. And, that's in relation to the previous years here, a fairly low level. We have been more around 60, 70, or even above that in some quarters. So we didn't have effects from previous quarters into this first quarter to a very large extent now. And the acquisitions we have made this quarter haven't really added enough yet. So, in this perspective, quarter two will have a better effect, more effect. But, you know that our goal is to really acquire around 20 companies per year. And I would say that we are at that pace this year now. And, in general, it's wise to basically follow our acquisition progress over a longer period of time since it can shift between quarters quite significantly. By that, I will leave the word over to Patrik to elaborate a little bit more about the financial performance. Yes. Thank you.